A Double-Blind, Randomized, 12-Month, Placebo-Controlled, Parallel Group, Fixed-Dose Study to Evaluate the Efficacy and Safety of AVE5530 25mg/Day and AVE5530 50 mg/Day in Patients With Primary Hypercholesterolemia.
Phase of Trial: Phase III
Latest Information Update: 17 May 2016
At a glance
- Drugs Canosimibe (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 22 Jul 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 May 2009 Planned end date changed from 1 Mar 2010 to 1 Jun 2009 as reported by ClinicalTrials.gov.